Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
The Better Food Disclosure Act of 2025 would amend the Federal Food, Drug, and Cosmetic Act to require notification to the FDA and the creation of a publicly accessible list of substances ‘‘generally recognized as safe’’ (GRAS). After transition periods (two years for existing GRAS uses; 120 days prior notice for new uses), a substance will be treated as unsafe for food use unless it is included on the FDA-maintained GRAS list or is under formal FDA review.
Default rule: liberals view deeming unlisted GRAS substances as unsafe as a needed corrective; conservatives view it as regulatory overreach.
Relative to its intended legislative type, this bill is a substantive regulatory reform that is well-integrated into existing statutory structure and provides specific procedural mechanisms and deadlines, but it lacks fiscal/resourcing provisions and leaves several implementation details to future rulemaking.
The Better Food Disclosure Act of 2025 would amend the Federal Food, Drug, and Cosmetic Act to require notification to the FDA and the creation of a publicly accessible list of substances ‘‘generally recognized as safe’’ (GRAS).
After transition periods (two years for existing GRAS uses; 120 days prior notice for new uses), a substance will be treated as unsafe for food use unless it is included on the FDA-maintained GRAS list or is under formal FDA review.
The bill requires FDA rulemaking to establish listing procedures, sets timelines for FDA action on notices, creates a process for exclusion, delisting, or reclassification of substances (including conversion to food additives), and establishes postmarket reevaluation procedures tied to citizen petitions and state notices.
Judged on content alone, the bill addresses a technically important but contentious regulatory area and would impose new mandatory obligations on industry while increasing FDA workload. Those features typically provoke concerted stakeholder resistance and require negotiation to secure broad support. The bill’s procedural safeguards and phased approach improve enactability compared with a blunt regulatory shift, but absent clear evidence of wide bipartisan coalition or accommodation of industry concerns (e.g., cost mitigation, longer phase-ins, appropriations for FDA), the probability of passage into law appears limited.
Relative to its intended legislative type, this bill is a substantive regulatory reform that is well-integrated into existing statutory structure and provides specific procedural mechanisms and deadlines, but it lacks fiscal/resourcing provisions and leaves several implementation details to future rulemaking.
Default rule: liberals view deeming unlisted GRAS substances as unsafe as a needed corrective; conservatives view it as regulatory overreach.
These are examples from the analysis, not a ranked list of the most-affected groups.
Default rule: liberals view deeming unlisted GRAS substances as unsafe as a needed corrective; conservatives view it as regulatory overreach.
A mainstream liberal would likely view this bill as a meaningful step to increase transparency and federal oversight of chemicals and other substances used in food.
They would see the requirement for a public FDA-maintained list, mandatory notifications, and a formal reevaluation pathway as closing a regulatory gap where industry self-affirmation of GRAS status previously occurred with limited public visibility.
The emphasis on career-scientist review and notice-and-comment rulemaking would be read positively as insulating safety determinations from political influence.
A pragmatic centrist would see the bill as a targeted regulatory modernization that addresses a recognized transparency gap around GRAS substances while creating predictable processes.
They would generally favor more FDA oversight but would be attentive to implementation details — especially the administrative cost to FDA, burdens on manufacturers, and potential impacts on supply chains or consumer prices.
A centrist would look for clear cost estimates, phased implementation, and safeguards to prevent unnecessary disruption to food availability.
A mainstream conservative would likely be skeptical of the bill because it shifts the default for GRAS substances to being ‘unsafe’ unless affirmatively listed by the FDA, which increases federal regulatory reach and compliance obligations for food manufacturers.
They would be concerned about regulatory costs, potential impacts on innovation and small businesses, and the expansion of FDA authority to reclassify substances via rulemaking.
Some conservatives might nevertheless appreciate the procedural protections that keep decisions with career scientists rather than political appointees, but overall the bill would be seen as an unnecessary regulatory expansion unless substantially narrowed or funded by the federal government rather than imposing new burdens on industry.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Judged on content alone, the bill addresses a technically important but contentious regulatory area and would impose new mandatory obligations on industry while increasing FDA workload. Those features typically provoke concerted stakeholder resistance and require negotiation to secure broad support. The bill’s procedural safeguards and phased approach improve enactability compared with a blunt regulatory shift, but absent clear evidence of wide bipartisan coalition or accommodation of industry concerns (e.g., cost mitigation, longer phase-ins, appropriations for FDA), the probability of passage into law appears limited.
The bill has not accumulated any surfaced votes yet.
Default rule: liberals view deeming unlisted GRAS substances as unsafe as a needed corrective; conservatives view it as regulatory overreac…
Judged on content alone, the bill addresses a technically important but contentious regulatory area and would impose new mandatory obligati…
Relative to its intended legislative type, this bill is a substantive regulatory reform that is well-integrated into existing statutory structure and provides specific procedural mechanisms and deadlines, but it lacks f…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.